---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Special populations"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Special populations. Topics: Age range studied and older adults; Men: eligibility and enrollment; Premenopausal women: ovarian suppression and enrollment; Pregnancy, lactation, and contraception requirements in clinical trials; 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/special-populations"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age range studied and older adults

> “18 Years and older”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Age, years; median (range) | “59.5 (30–81)” | “61.0 (32–85)” | “61.0 (30–85)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
| --- | --- | --- | --- |
| Median age, yrs (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.8-2"></a>

### Men: eligibility and enrollment

> “Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Female, n (%) | “30 (100)” | “86 (100)” | “116 (100)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic, n (%) | Total (N = 46) |
| --- | --- |
| Female sex | “45 (98)” |
| Premenopausal | “4 (9)” |

Source: [Chan et al. (2023b)](https://olema.com/wp-content/uploads/2023/12/Olema_Final_SABCS2023-OP-1250-002_12-6-23.pdf)

<a id="topic-2.1.2.8-3"></a>

### Premenopausal women: ovarian suppression and enrollment

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Female participants can be pre-, peri- or postmenopausal.”
> “Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.”

Source: [ClinicalTrials.gov NCT06016738](https://clinicaltrials.gov/study/NCT06016738)

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Childbearing potential: yes, n (%) | “0” | “7 (8.1)” | “7 (6.0)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “The reproductive status of female participants has been reported as having a childbearing potential (yes vs no)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

| Characteristic | 90 mg + ribociclib (n = 16) | 120 mg + ribociclib (n = 56) | Total (N = 72) |
| --- | --- | --- | --- |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.8-4"></a>

### Pregnancy, lactation, and contraception requirements in clinical trials

> “Willingness to use effective contraception”
> “Pregnancy or breastfeeding”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Males and females of childbearing age must be willing to use effective contraception during the study and for 90 days or longer, following the last dose of study treatment”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-5"></a>

### Nonclinical reproductive and developmental toxicology

No evidence found.

<a id="topic-2.1.2.8-6"></a>

### Class context: embryo-fetal toxicity with imlunestrant

> “In an animal reproduction study, oral administration of imlunestrant to pregnant rats during the period of organogenesis led to embryo-fetal mortality and structural abnormalities at maternal exposures that were below the human exposure at the recommended dose based on AUC.”
> “Advise females of reproductive potential to use effective contraception during treatment with INLURIYO and for 1 week after the last dose.”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.1.2.8-7"></a>

### Hepatic impairment: trial exclusion criteria

> “a clinically significant history of liver disease consistent with Child–Pugh class B or C”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Adequate hepatic function”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis (eg, hepatitis B or hepatitis C virus), current alcohol abuse, or cirrhosis.”

Source: [ClinicalTrials.gov NCT05508906](https://clinicaltrials.gov/study/NCT05508906)

> “Adequate hematologic, renal, hepatic, and coagulation function”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-8"></a>

### Renal impairment: trial exclusion criteria

> “Adequate renal function”
> “Significant renal disease”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="topic-2.1.2.8-9"></a>

### Hepatic and renal impairment: dedicated pharmacokinetic studies

No evidence found.

<a id="topic-2.1.2.8-10"></a>

### Central nervous system metastases: phase 2 cohort and exclusion from OPERA-01

> “Cohort A will enroll subjects with measurable disease without evidence of Central Nervous System (CNS) metastases; Cohort B will enroll subjects with non-measurable (evaluable) disease without evidence of CNS metastases; and Cohort C will enroll subjects with evaluable disease (measurable and non-measurable) with CNS metastases.”

Source: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

> “Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and CNS metastases (exploratory cohort, not included in this report).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

> “Palazestrant has demonstrated activity in both ESR1-wild type (ESR1-wt) and ESR1-mutated (ESR1-mut) preclinical models as well as central nervous system (CNS) penetration and demonstrated antitumor activity in brain metastasis models.”
> “CNS metastases, carcinomatous meningitis, leptomeningeal disease, or spinal cord compression that requires immediate CNS-directed treatment”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.8-11"></a>

### Race of participants in the phase 1/2 monotherapy trial

| Race, n (%) | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| White | “23 (76.7)” | “70 (81.4)” | “93 (80.2)” |
| Black or African American | “1 (3.3)” | “7 (8.1)” | “8 (6.9)” |
| Asian | “1 (3.3)” | “3 (3.5)” | “4 (3.4)” |
| Not reported/Other | “5 (16.7)” | “6 (7.0)” | “11 (9.5)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
